Increased PRAME-Specific CTL Killing of Acute Myeloid Leukemia Cells by Either a Novel Histone Deacetylase Inhibitor Chidamide Alone or Combined Treatment with Decitabine

AJ Simpson, 2005, Cancer/testis antigens, gametogenesis and cancer, Nat Rev Cancer, 5, 615, 10.1038/nrc1669

MJ Scanlan, 2002, Cancer/testis antigens: an expanding family of targets for cancer immunotherapy, Immunol Rev, 188, 22, 10.1034/j.1600-065X.2002.18803.x

D Atanackovic, 2011, Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia, Am J Hematol, 86, 918, 10.1002/ajh.22141

MT Epping, 2005, The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling, Cell, 122, 835, 10.1016/j.cell.2005.07.003

J Greiner, 2006, Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches, Blood, 108, 4109, 10.1182/blood-2006-01-023127

CA Ortmann, 2008, Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia, Ann Hematol, 87, 809, 10.1007/s00277-008-0514-8

N van Baren, 1998, PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells, Br J Haematol, 102, 1376, 10.1046/j.1365-2141.1998.00982.x

M Griffioen, 2006, Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy, Clin Cancer Res, 12, 3130, 10.1158/1078-0432.CCR-05-2578

JH Kessler, 2001, Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis, J Exp Med, 193, 73, 10.1084/jem.193.1.73

M Yan, 2011, Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2′-Deoxycytidine, Cancer Immunol Immunother, 60, 1243, 10.1007/s00262-011-1024-4

C Quintarelli, 2008, Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia, Blood, 112, 1876, 10.1182/blood-2008-04-150045

SM Pollack, 2012, NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine, PLoS One, 7, e32165, 10.1371/journal.pone.0032165

K Rezvani, 2009, Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia, Blood, 113, 2245, 10.1182/blood-2008-03-144071

DC Drummond, 2005, Clinical development of histone deacetylase inhibitors as anticancer agents, Annu Rev Pharmacol Toxicol, 45, 495, 10.1146/annurev.pharmtox.45.120403.095825

M Szyf, 2009, Epigenetics, DNA methylation, and chromatin modifying drugs, Annu Rev Pharmacol Toxicol, 49, 243, 10.1146/annurev-pharmtox-061008-103102

CR Cruz, 2011, Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4, Clin Cancer Res, 17, 7058, 10.1158/1078-0432.CCR-11-1873

JA Dubovsky, 2009, Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen, Clin Cancer Res, 15, 3406, 10.1158/1078-0432.CCR-08-2099

K Gong, 2012, CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells, Biochem J, 443, 735, 10.1042/BJ20111685

L Liu, 2010, A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells, Biochem Biophys Res Commun, 392, 190, 10.1016/j.bbrc.2010.01.011

A Natsume, 2008, The DNA demethylating agent 5-aza-2′-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma, Int J Cancer, 122, 2542, 10.1002/ijc.23407

S Skov, 2005, Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res, 65, 11136

DD Vo, 2009, Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824, Cancer Res, 69, 8693, 10.1158/0008-5472.CAN-09-1456

J Weber, 1994, Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2′-deoxycytidine, Cancer Res, 54, 1766

TS Weiser, 2001, Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1, J Immunother, 24, 151, 10.1097/00002371-200103000-00010

O Goodyear, 2010, Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia, Blood, 116, 1908, 10.1182/blood-2009-11-249474

SN Akers, 2010, Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy, Future Oncol, 6, 717, 10.2217/fon.10.36

LE Rossi, 2012, Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression, J Leukoc Biol, 91, 321, 10.1189/jlb.0711339

BR Rosborough, 2012, Histone deacetylase inhibition facilitates GM-CSF-mediated expansion of myeloid-derived suppressor cells in vitro and in vivo, J Leukoc Biol, 91, 701, 10.1189/jlb.0311119

W Song, 2011, HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells, Leukemia, 25, 161, 10.1038/leu.2010.244

L Shen, 2012, Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models, PLoS One, 7, e30815, 10.1371/journal.pone.0030815

ZQ Ning, 2012, Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity, Cancer Chemother Pharmacol, 69, 901, 10.1007/s00280-011-1766-x

T Maeda, 2000, Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells, Blood, 96, 3847, 10.1182/blood.V96.12.3847

SR Riddell, 1990, The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells, J Immunol Methods, 128, 189, 10.1016/0022-1759(90)90210-M

S Xia, 2008, Liver stroma enhances activation of TLR3-triggered NK cells through fibronectin, Mol Immunol, 45, 2831, 10.1016/j.molimm.2008.01.035

MT Epping, 2007, A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors, Proc Natl Acad Sci U S A, 104, 17777, 10.1073/pnas.0702518104

C Santamaria, 2008, The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia, Haematologica, 93, 1797, 10.3324/haematol.13214

D Steinbach, 2002, Clinical implications of PRAME gene expression in childhood acute myeloid leukemia, Cancer Genet Cytogenet, 133, 118, 10.1016/S0165-4608(01)00570-2

N Tajeddine, 2008, Tumor associated antigen PRAME is a marker of favorable prognosis in childhood acute myeloid leukemia patients and modifies the expression of S100A4, Hsp 27, p21, IL-8 and IGFBP-2 in vitro and in vivo, Leuk Lymphoma, 49, 1123, 10.1080/10428190802035933

P Doolan, 2008, Prevalence and prognostic and predictive relevance of PRAME in breast cancer, Breast Cancer Res Treat, 109, 359, 10.1007/s10549-007-9643-3

A Oberthuer, 2004, The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome, Clin Cancer Res, 10, 4307, 10.1158/1078-0432.CCR-03-0813

BM Carreno, 2002, The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses, Annu Rev Immunol, 20, 29, 10.1146/annurev.immunol.20.091101.091806

AH Sharpe, 2002, The B7-CD28 superfamily, Nat Rev Immunol, 2, 116, 10.1038/nri727

DR Fooksman, 2010, Functional anatomy of T cell activation and synapse formation, Annu Rev Immunol, 28, 79, 10.1146/annurev-immunol-030409-101308

T Qin, 2007, Effect of cytarabine and decitabine in combination in human leukemic cell lines, Clin Cancer Res, 13, 4225, 10.1158/1078-0432.CCR-06-2762

P Agarwal, 2009, Gene regulation and chromatin remodeling by IL-12 and type I IFN in programming for CD8 T cell effector function and memory, J Immunol, 183, 1695, 10.4049/jimmunol.0900592

J Choi, 2010, In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia, Blood, 116, 129, 10.1182/blood-2009-12-257253

2006, Histone acetylation is associated with differential gene expression in the rapid and robust memory CD8(+) T-cell response, Blood, 108, 3363, 10.1182/blood-2006-02-005520

P Reddy, 2008, Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice, J Clin Invest, 118, 2562

JK Northrop, 2008, Cutting edge: chromatin remodeling as a molecular basis for the enhanced functionality of memory CD8 T cells, J Immunol, 181, 865, 10.4049/jimmunol.181.2.865

S Carta, 2006, Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of microtubules, Blood, 108, 1618, 10.1182/blood-2006-03-014126